Mark T. Iwicki
Net Worth
Last updated:
What is Mark T. Iwicki net worth?
The estimated net worth of Mr. Mark T. Iwicki is at least $7,562,302 as of 26 Jun 2024. He owns shares worth $2,260,380 as insider, has earned $221,922 from insider trading and has received compensation worth at least $5,080,000 in Kala Pharmaceuticals, Inc..
What is the salary of Mark T. Iwicki?
Mr. Mark T. Iwicki salary is $1,270,000 per year as Chairman & Chief Executive Officer in Kala Pharmaceuticals, Inc..
How old is Mark T. Iwicki?
Mr. Mark T. Iwicki is 59 years old, born in 1966.
What stocks does Mark T. Iwicki currently own?
As insider, Mr. Mark T. Iwicki owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Kala Pharmaceuticals, Inc. (KALA) | Chairman & Chief Executive Officer | 263,755 | $8.57 | $2,260,380 |
What does Kala Pharmaceuticals, Inc. do?
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
Mark T. Iwicki insider trading
Kala Pharmaceuticals, Inc.
Mr. Mark T. Iwicki has made 9 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 15,168 units of KALA stock worth $72,048 on 26 Jun 2024.
The largest trade he's ever made was exercising 27,598 units of KALA stock on 26 Oct 2021. As of 26 Jun 2024 he still owns at least 263,755 units of KALA stock.